Blog

Colorectal Cancer

Feb 2, 2025, 04:22

Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a paper by Scott Kopetz et al. on X:

“Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer:

BREAKWATER Phase 3 trial
ORR 60% vs. 40.0%
DoR 13.9 vs. 11.1 months
OS NE vs. 14.6 months

New SOC for BRAF mutant CRC”

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

Authors: Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Singh Wasan, Jayesh Desai, Fortunato Ciardiello, Rona Yaeger, Timothy S. Maughan, Elena Beyzarov, Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang & Josep Tabernero

Encorafenib, cetuximab, and chemotherapy in BRAF-mutant colorectal cancer

Arndt Vogel BRAF mutant CRC BRAF mutation BREAKWATER trial cancer Cancer research cancer treatment cetuximab chemotherapy clinical trials colorectal cancer CRC outcomes encorafenib ESMO Nature Medicine OncoDaily Oncology Phase 3 Trial Precision Oncology SoC survival data targeted therapy

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25